leuprolide acetate for depot suspension / Generic mfg. - LARVOL DELTA

Nicolau Syndrome in a Child: A Rare Injection-Related Complication (AAD 2026) - "We present a pediatric case of NS following IM leuprolide...He was treated with antihistamines, NSAIDs, and a prednisone injection...Although etiology remains unclear, NS is considered an unpredictable complication independent of number of injections or medication type, dose, or injection frequency, and recurrence is not expected. This case adds to limited pediatric literature, highlights diagnostic challenges, and supports continued IM injection use when clinically indicated."

Clinical • Bone Marrow Transplantation • Cardiovascular • Hematological Disorders • Thrombosis

Incidence of Early Ovarian Suppression Failure in Premenopausal Breast Cancer Patients at an Academic Medical Center (HOPA 2026) - "Patients were included if they had received leuprolide, triptorelin, and/or goserelin and had an estradiol level drawn between January 2024 and October 2025. In progress In progress"

Clinical • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Infectious Disease • Oncology • Solid Tumor

Leuprolide Acetate Promotes Sensory Recovery and Modulates Dorsal Root Ganglion Responses After Sciatic Nerve Transection in Rats. (PubMed, Brain Sci) - " Our results showed that LA treatment exerted a distinct neurotrophic effect, since it promoted the specific recovery of cold sensitivity, improved axonal transport, regulated the inflammatory response, and modulated the exacerbated expression of pro-regenerative genes in the SNT model. These findings indicate that LA therapy may have the potential to improve sensory recovery in patients with sciatic nerve injuries."

Journal • Preclinical • Inflammation • ATF4 • SOCS3 • STAT3

Effect of Vitamin K Supplementation on Testosterone Production in a Rat Model of Late-Onset Hypogonadism. (PubMed, Foods) - "In this study, we investigated the effects of VK on LOH using a leuprorelin acetate (LA)-induced low-Ts rat model...Furthermore, MK-4 supplementation activated the protein kinase A signaling pathway, which is directly involved in testicular Ts production. These findings suggest that MK-4 supplementation may represent a novel nutritional strategy for the management of LOH."

Journal • Preclinical • Endocrine Disorders

Network-based discovery of tumor-checkpoint inverter drugs targeting pancreatic ductal adenocarcinoma cell states and macrophage reprogramming (AACR 2026) - "Cross-model validation identified state-specific candidate drugs, including Leuprolide, Vinblastine, and Mercaptopurine for GLS; Vindesine, Gossypol, and Binimetinib for MOS; and AT9283, Crizotinib, and Afatinib for PLS. Predicted MR-inversion scores correlated with experimental dose-response profiles in cell lines selected via OncoMatch.Together, these results establish a mechanistic link between tumor-intrinsic transcriptional states and macrophage immunosuppression, while identifying mutation-agnostic, state-specific drugs capable of reprogramming both tumor and immune compartments. This work provides a generalizable framework for network-based drug repurposing to overcome transcriptional plasticity and immune resistance in PDAC."

Oncology • Pancreatic Ductal Adenocarcinoma • APOE

Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy. (PubMed, Eur Urol Oncol) - P2 | "All patients received 6 mo of intensified systemic therapy (leuprolide, abiraterone acetate with prednisone, and apalutamide) and stereotactic body radiotherapy to oligometastases. Among 50 patients (24 synchronous and 26 metachronous), the synchronous omCSPC group had a significantly higher PSA response rate (83% vs 50%; p = 0.018) and significantly longer PFS and eugonadal PFS (p < 0.05). The metachronous subgroup with prior ADT had worse outcomes, suggesting increasing resistance with repeated systemic therapy."

Journal • Retrospective data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Coronary Artery Plaque Progression After Androgen Deprivation Therapy in Men with Prostate Cancer: A Randomized Controlled Trial Comparing Relugolix Versus Leuprolide (SUO 2025) - P2 | "ADT for prostate cancer is associated with accelerated coronary atherosclerosis within 12 months and is higher with GnRH-agonist leuprolide compared with GnRH-antagonist relugolix."

Clinical • Acute Coronary Syndrome • Atherosclerosis • Coronary Artery Disease • Genito-urinary Cancer • Myocardial Infarction • Oncology • Prostate Cancer • Solid Tumor

Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate Cancer. (PubMed, Eur Urol Oncol) - "Leuprorelin treatment immediately after RP in high-risk nonmetastatic PCa patients with an undetectable PSA level does not improve survival, but increases adverse events, leading to poorer quality of life compared with observation."

Journal • P3 data • CNS Disorders • Fatigue • Genito-urinary Cancer • Mental Retardation • Oncology • Pain • Prostate Cancer • Psychiatry • Solid Tumor

Are long-term remissions possible with hormonal therapy only? Post hoc analysis of EMBARK examining sustained prostate-specific antigen (PSA) <0.2 ng/mL despite testosterone (T) recovery after treatment (tx) suspension. (ASCO-GU 2026) - P3 | "Background: The phase 3 EMBARK trial (NCT02319837) assessed enzalutamide plus leuprolide (enza combo), leuprolide alone (LA), and enzalutamide monotherapy (enza mono) in patients (pts) with prostate cancer and high-risk biochemical recurrence. Approximately 1 in 25 pts treated with enza combo for 9 months had PSA <0.2 ng/mL and normal T 3 years post therapy, demonstrating long-term "remissions" are possible after only 9 months of enza combo. Rates with LA and enza mono were not zero but were much lower than with enza combo (both 1%, vs 4% with enza combo). Pts with PSA <0.2 ng/mL and T recovery after tx suspension (safety population)."

Clinical • Retrospective data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Apalutamide + Abiraterone acetate plus Prednisone (AAP) + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase 2 Study. (PubMed, Clin Cancer Res) - "Treatment intensification with apalutamide, AAP, ADT and SBRT well-tolerated with limited impact on quality of life. While BCR rates exceed the superiority threshold, outcomes aligned with historical benchmarks, supporting further evaluation of the regimen in prospective trials."

Journal • P2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Case Report: Successful natural conception and delivery in a primary cancer survivor involving the reproductive, respiratory, and endocrine systems auth. (PubMed, Front Oncol) - "She received six cycles of postoperative leuprorelin therapy...The polyp was resected, and the patient received a 14-day course of anti-infective therapy with metronidazole and levofloxacin, after which she was guided by natural conception...It establishes an MDT management pathway encompassing "determination of oncologic remission status, intervention for reversible fertility-compromising factors, and cross-trimester monitoring." This confirms that natural pregnancy is safe and feasible for patients in cancer remission, with multi-disciplinary collaboration and rigorous monitoring. The absence of postpartum neoplasm recurrence and abnormalities in offspring provides a practical paradigm for fertility management in patients with MPNs."

Journal • Endometriosis • Gynecology • Lung Cancer • Obstetrics • Oncology • Ovarian Cancer • Solid Tumor • Thyroid Gland Carcinoma • Women's Health • HER-2

Ultra-hypofractionated radiotherapy and concomitant oral relugolix for treatment of intermediate risk prostate cancer (ULTRA-HERO). (ASCO-GU 2026) - "Relugolix is an oral, highly selective, GnRH antagonist recently tested in a randomized phase III trial showing reduced risk in terms of cardiovascular events and rapid testosterone recovery if compared to Leuprolide. Enrollment started in May 2025 and 20 patients have been enrolled up to date. A final sample size of sample size of 73 patients will be needed to estimate the expected proportion of patients with complete biochemical response with a 5% precision margin and a 95% confidence interval."

Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

EMBARK: Overall survival with enzalutamide in biochemically recurrent prostate cancer (ESMO 2025) - P3 | "Background The phase 3 EMBARK trial (NCT02319837) showed significant improvements in metastasis-free survival (MFS) and secondary efficacy endpoints with enzalutamide plus leuprolide (enza combo) and enzalutamide monotherapy (enza mono) vs leuprolide alone (LA). ‖ P <0.0499 was statistically significant. ¶ Nominal P -value."

Clinical • Late-breaking abstract • Genito-urinary Cancer • Oncology • Prostate Cancer

Effect of Medical Therapies for Endometriosis on Bone Health: A Systematic Review and Meta-analysis. (PubMed, Obstet Gynecol) - "Hormonal suppression for endometriosis treatment is associated with a decrease in BMD after 12 months of use, with each medical therapy having a unique effect. The clinical significance of these findings remains uncertain, highlighting the need for expert consensus for bone health management in patients on long-term hormonal therapy."

Journal • Retrospective data • Endometriosis • Gynecology • Women's Health

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Icahn School of Medicine at Mount Sinai | Not yet recruiting ➔ Recruiting | Initiation date: Jun 2025 ➔ Mar 2026

Enrollment open • Trial initiation date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • CTLA4

A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor (SGO 2026) - No abstract available

Clinical • Combination therapy • P2 data • Oncology • Ovarian Cancer

Research Status of Androgen Deprivation Therapy Monotherapy and Combination Therapy for Prostate Cancer: A Scoping Review. (PubMed, Cancer Manag Res) - "There were 52, 67, ten, and 16 studies evaluating leuprorelin, goserelin, triptorelin, and degarelix, respectively. Although numerous studies have evaluated the efficacy of ADT drugs for the treatment of PC, there is still a paucity of high-quality research across multiple domains. Furthermore, there is a relative lack of in-depth research involving Chinese patients."

Journal • Monotherapy • Review • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Differential cardiometabolic outcomes of leuprolide versus spironolactone in women with polycystic ovary syndrome. (PubMed, Proc (Bayl Univ Med Cent)) - "Leuprolide therapy was associated with improved lipid and hypertension outcomes compared to spironolactone. These findings support leuprolide's potential role in broader metabolic management of PCOS."

Journal • Cardiovascular • Chronic Kidney Disease • Diabetes • Dyslipidemia • Endocrine Disorders • Genetic Disorders • Hypertension • Metabolic Disorders • Nephrology • Obesity • Polycystic Ovary Syndrome • Renal Disease

IMPACT OF CLONAL HEMATOPOIESIS ON ANDROGEN DEPRIVATION THERAPY-ASSOCIATED CORONARY PLAQUE PROGRESSION IN MEN WITH PROSTATE CANCER: A SECONDARY ANALYSIS OF THE REVELUTION RANDOMIZED CLINICAL TRIAL (ACC 2026) - P2 | " We conducted a secondary analysis of REVELUTION (NCT05320406), a randomized trial comparing gonadotropin-releasing hormone (GnRH)-agonist leuprolide versus GnRH-antagonist relugolix on coronary plaque progression in men with localized PCa receiving prostate radiation therapy (RT), all of whom underwent CCTA at baseline and again at 12 months after ≥6 months of ADT. CH may amplify coronary plaque progression in men with prostate cancer receiving RT or GnRH-agonist therapy."

Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A RARE CASE OF ENZALUTAMIDE-ASSOCIATED CARDIOMYOPATHY IN A PATIENT WITH ATTR CARDIAC AMYLOIDOSIS (ACC 2026) - "It has demonstrated a more favorable side-effect profile compared to its predecessor; abiraterone, although cardiovascular (CV) toxicities have been reported, including hypertension, ischemic heart disease, and QT prolongation...Case: A 77-year-old male with hypertension, pre-diabetes, hereditary transthyretin cardiac amyloidosis (Val142Ile mutation) with preserved cardiac function on tafamidis, and PCa managed with leuprolide and recent addition of Enzalutamide, presented with acute systolic HF... Current published literature on Enzalutamide-associated cardiomyopathy remains limited. Further research is needed to better understand Enzulatamide associated CV toxicity, including mechanisms of toxicity and patient specific and treatment related risk factors to optimize cancer-related outcomes and mitigate potential CV side effects."

Clinical • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Genito-urinary Cancer • Heart Failure • Hypertension • Prostate Cancer • Solid Tumor

Prostate Cancer Metastasis (AAD 2026) - "Patient History: 82 year old male with a past medical history significant for metastatic prostate cancer status post prostatectomy with eventual biochemical recurrence and subsequent adjuvant therapy consisting of GnRH agonist (Leuprorelin), salvage radiotherapy, abiraterone with prednisone, docetaxel and olaparib treatments. Treatment includes but is not limited to excision, chemotherapy, immunotherapy and in some instances radiotherapy for palliative purposes. Our patient underwent palliative radiation for the aforementioned skin metastases with symptomatic improvement and lesion involution."

Anorexia • Gastrointestinal Disorder • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • NKX3-1 • SOX10

Fixed Dosing of Leuprolide Acetate, a GnRH Agonist, in Children with Central Precocious Puberty: A Population Pharmacokinetic Justification. (PubMed, Paediatr Drugs) - P3 | "The developed model adequately characterized leuprolide pharmacokinetics in pediatrics. No significant covariate effects were observed, supporting the use of a fixed leuprolide dose in pediatrics."

Journal • PK/PD data • Endocrine Disorders • Genito-urinary Cancer • Oncology • Pediatrics • Prostate Cancer • Solid Tumor

UC-BCG-2501: NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early breast cancer treated with Ribociclib (LEE-011) innthe adjuvant setting (clinicaltrialsregister.eu) - P2/3 | N=3306 | Recruiting | Sponsor: Unicancer

Head-to-Head • New P2/3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

A case of type 2 diabetes with spinal and bulbar muscular atrophy treated with oral semaglutide while sparing muscle reduction for two years: a case report with literature review. (PubMed, Diabetol Int) - "Semaglutide has demonstrated beneficial effects in patients with type 2 diabetes; however, its long-term impact on skeletal muscle remains uncertain, particularly in individuals with multiple risk factors for muscle decline. Importantly, skeletal muscle mass and strength were relatively preserved, with only a minor annual decrease in muscle mass (- 0.1 kg/year), consistent with changes reported in previous studies of semaglutide-treated patients without neuromuscular conditions. To our knowledge, this is the first reported case describing the use of semaglutide in a patient with diabetes and SBMA under leuprorelin treatment, suggesting the potential utility of GLP-1 receptor agonists in managing metabolic parameters in individuals at high risk for muscle decline."

Journal • Diabetes • Metabolic Disorders • Muscular Atrophy • Type 2 Diabetes Mellitus

Effects of obesity on biphasic immune remodeling of CD45⁺ circulating cells during androgen deprivation therapy in prostate cancer. (ASCO-GU 2026) - " Forty-four blood samples from 19 men with treatment-naïve prostate cancer (median age 66 years; 11 Black, 8 White; 10 obese [BMI ≥ 30]) were collected at baseline (A), 1 month (B), and 3 months (C) after leuprolide...By 3 months, monocytes rebounded (cMo +1.08, nMo +1.48) with far greater amplitude in obese men (cMo +2.93 vs –1.14; nMo +1.89 vs +0.67)... ADT drives a biphasic remodeling of circulating CD45⁺ immunity—an early, adiposity-modulated cytotoxic shift followed by an obesity-amplified monocyte rebound. These data highlight how metabolic state shapes immune plasticity under androgen deprivation and may inform cardio-oncologic risk. Baseline characteristics of men initiating ADT."

Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD8 • PTPRC